TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1977761

Group type: EXPERIMENTAL
Intervention: Clonidine (0.150 mg, orally) followed by GHRH (1 micrograms/kg, iv) at 180 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clonidine (0.150 mg, orally) at 0 min followed by GHRH at 60 min and again at 180 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo followed by GHRH at 60 min and again at 180 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clonidine at 0 min followed by 2 GHRH challenges (60 and 180 min later)
Number of subjects: 10
Study: 632137

Group type: EXPERIMENTAL
Intervention: AGC (compression) system
Number of subjects: 34

Group type: COMPARATOR
Intervention: PC (peac‐clipping) system
Number of subjects: 34
Study: 30932958

Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 373

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 373
Study: 28923101

Group type: EXPERIMENTAL
Intervention: Achieving Durable Response (DR)
Number of subjects: 436
Study: 25818049

Group type: EXPERIMENTAL
Intervention: 80mg of propranolol hydrochloride (β1 and β2 adrenergic receptor antagonist)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Microcrystalline cellulose (placebo pill)
Number of subjects: 16
Study: 24314119

Group type: EXPERIMENTAL
Intervention: Yoga at home (n = 28)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Yoga class with yoga instructor (n = 28)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (n = 27)
Number of subjects: 83
Study: 21035395

Group type: EXPERIMENTAL
Intervention: Restriction of blood flow (RBF) group with external compressive force of 50 mm Hg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (CON) group with no intervention
Number of subjects: 11
Study: 19162406

Group type: EXPERIMENTAL
Intervention: Female-specific group motivational enhancement intervention (n=161)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control group (n=126)
Number of subjects: 287
Study: 17091358

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 160
Study: 15612964

Group type: EXPERIMENTAL
Intervention: Zafirlukast, 20 mg bd
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Budesonide inhaler, 200 microg bd
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Theophylline, 200 mg bd
Number of subjects: 30
Study: 12572722

Group type: EXPERIMENTAL
Intervention: Ciclopiroxolamine cream 11% (group A)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ciclopiroxolamine solution 1% (group B)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Boric acid (group C)
Number of subjects: 64
Study: 9435425

Group type: EXPERIMENTAL
Intervention: GH treatment (0.125 U/kg per week for 1 month and 0.25 U/kg per week for 5 months)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 166
Study: 7642756

Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy (SRT)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 32
Study: 2568817

Group type: EXPERIMENTAL
Intervention: Iopromide 370 (2 ml/kg body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iopamidol 370 (2 ml/kg body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium meglumine diatrizoate 370 (2 ml/kg body weight)
Number of subjects: 0
Study: 411723

Group type: EXPERIMENTAL
Intervention: Chlorpropamide (Diabenese)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glibenclamide (Daonil)
Number of subjects: 0
Study: 31604062

Group type: EXPERIMENTAL
Intervention: 44 g (250 kcal) pistachios consumed mid‐morning
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group maintained current eating habits
Number of subjects: 60
Study: 31634286

Group type: EXPERIMENTAL
Intervention: TCC early intervention (patient education, peer visits, coaching calls)
Number of subjects: 787
Study: 28178092

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided sacral lateral branch blocks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoroscopy-guided sacral lateral branch blocks
Number of subjects: 40
Study: 26449617

Group type: COMPARATOR
Intervention: AMG 403 (1, 3, 10, or 30 mg intravenously; or 10 or 30 mg subcutaneously)
Number of subjects: 66

Group type: COMPARATOR
Intervention: AMG 403 (3, 10, or 20 mg subcutaneously once monthly for four doses)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 24106072

Group type: EXPERIMENTAL
Intervention: Sildenafil (optimized dose)
Number of subjects: 140
Study: 22042739

Group type: EXPERIMENTAL
Intervention: Nurse practitioner embedded in a resident team
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no nurse practitioner)
Number of subjects: 0
Study: 19344824

Group type: EXPERIMENTAL
Intervention: Investigator classification of retinal vein occlusion
Number of subjects: 682

Group type: COMPARATOR
Intervention: Reading Center classification of retinal vein occlusion
Number of subjects: 682
Study: 16784743

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15068413

Group type: EXPERIMENTAL
Intervention: 1 week of therapy (lansoprazole 30 mg b.i.d., amoxycillin 1 g b.i.d., tinidazole 500 mg b.i.d.)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 2 weeks of therapy (lansoprazole 30 mg b.i.d., amoxycillin 1 g b.i.d., tinidazole 500 mg b.i.d.)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 3 weeks of therapy (lansoprazole 30 mg b.i.d., amoxycillin 1 g b.i.d., tinidazole 500 mg b.i.d.)
Number of subjects: 64
Study: 11398593

Group type: EXPERIMENTAL
Intervention: Women with osteoporosis and severe osteoporosis
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (20 healthy women at perimenopausal age)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Women with osteopenia
Number of subjects: 53
Study: 8931202

Group type: EXPERIMENTAL
Intervention: Empirical Bayes estimates from a random effects model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empirical Bayes estimates from a stochastic regression model
Number of subjects: 0
Study: 1673505

Group type: EXPERIMENTAL
Intervention: Moderate alcohol intake (26 g alcohol daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Complete abstention from alcohol
Number of subjects: 87
Study: 7181084

Group type: EXPERIMENTAL
Intervention: Cimetidine (oral and intramuscular)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular Cimetidine
Number of subjects: 0
Study: 29634593

Group type: EXPERIMENTAL
Intervention: Structured toothbrushing program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study: 29211681

Group type: EXPERIMENTAL
Intervention: SBWP+MM (Standard Behavioral Weight Loss Program with Mindfulness Meditation)
Number of subjects: 46

Group type: COMPARATOR
Intervention: SBWP (Standard Behavioral Weight Loss Program)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: SBWP+MM
Number of subjects: 46
Study: 25993386

Group type: EXPERIMENTAL
Intervention: Light anesthesia (BIS target of 50)
Number of subjects: 3250

Group type: COMPARATOR
Intervention: Deep anesthesia (BIS target of 35)
Number of subjects: 3250
Study: 25184862

Group type: EXPERIMENTAL
Intervention: High-dose melphalan plus stem-cell transplantation
Number of subjects: 273

Group type: COMPARATOR
Intervention: MPR (melphalan-prednisone-lenalidomide)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance therapy
Number of subjects: 273

Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: High-dose melphalan
Number of subjects: 273

Group type: COMPARATOR
Intervention: MPR
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Number of subjects: 273
Study: 22529964

Group type: COMPARATOR
Intervention: HIV vaccine (placebo-controlled trial)
Number of subjects: 4684

Group type: EXPERIMENTAL
Intervention: Age 18-30 years
Number of subjects: 4684

Group type: EXPERIMENTAL
Intervention: Having >10 partners
Number of subjects: 4684

Group type: EXPERIMENTAL
Intervention: Having a known HIV-positive male sex partner
Number of subjects: 4684

Group type: EXPERIMENTAL
Intervention: Unprotected anal intercourse with HIV positive/unknown male partners
Number of subjects: 4684

Group type: EXPERIMENTAL
Intervention: Amphetamine use
Number of subjects: 4684

Group type: EXPERIMENTAL
Intervention: Popper use
Number of subjects: 4684
Study: 20601891

Group type: EXPERIMENTAL
Intervention: Ultrasound combined with neurostimulation
Number of subjects: 93

Group type: COMPARATOR
Intervention: Neurostimulation alone
Number of subjects: 93
Study: 17907290

Group type: EXPERIMENTAL
Intervention: Esophagogastric devascularization and splenectomy (EGDS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 36
Study: 16246675

Group type: EXPERIMENTAL
Intervention: Ultrathin transnasal endoscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluoroscopic placement
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ultrathin transnasal endoscopy (first 10 procedures)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ultrathin transnasal endoscopy (last 10 procedures)
Number of subjects: 100
Study: 11908570

Group type: EXPERIMENTAL
Intervention: Subtalar strapping insoles (n = 34)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Talonavicular strapping insoles (n = 37)
Number of subjects: 71
Study: 10407505

Group type: EXPERIMENTAL
Intervention: Fluvastatin therapy
Number of subjects: 363

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 363
Study: 7590051

Group type: EXPERIMENTAL
Intervention: Graded compression leg bandages (Group 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No graded compression leg bandages (Group 1)
Number of subjects: 24
Study: 2598983

Group type: COMPARATOR
Intervention: Intravenous nifedipine (0.75 mg bolus and 1.2 mg.h‐1 infusion for 2 h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral nifedipine (20 mg sustained-release)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vehicle alone (control for intravenous study)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control for oral study)
Number of subjects: 18
Study: 806518

Group type: EXPERIMENTAL
Intervention: Proteolytic enzymes (Chymoral)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Enteric-coated lactose tablets (Control)
Number of subjects: 50
Study: 31010413

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once-daily (QD)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo followed by Duloxetine 60 mg QD (PLA_DLX)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD (DLX_DLX)
Number of subjects: 342
Study: 28493924

Group type: EXPERIMENTAL
Intervention: Adaptive cognitive remediation (ACR) program
Number of subjects: 135

Group type: COMPARATOR
Intervention: Active control of ordinary computer games
Number of subjects: 135
Study: 26381208

Group type: EXPERIMENTAL
Intervention: Laser phototherapy (LPT) with a GaAlAs diode laser (808 nm, 100 mW, 0.04 cm², 75 J/cm², 30s per point, 3 J per point, at five points)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no irradiation)
Number of subjects: 20
Study: 23674838

Group type: EXPERIMENTAL
Intervention: Progressively reduced nicotine content (RNC) cigarettes
Number of subjects: 30
Study: 21163595

Group type: EXPERIMENTAL
Intervention: Synthetic genistein (30 mg daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 19584379

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study: 21042325

Group type: EXPERIMENTAL
Intervention: Dietary intervention (weight loss phase 0-6 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary intervention (weight maintenance/regain phase 7-24 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher baseline high-molecular-weight adiponectin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-month plasma leptin reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with greater (top tertiles) 6-month decrease in both weight and leptin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic variations in LEP (rs4731426 and rs2071045)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding genetic data to the phenotypic multivariate model
Number of subjects: 0
Study: 15840313

Group type: EXPERIMENTAL
Intervention: Serum CA(125) levels in patients with pelvic tuberculosis
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Serum CA(125) levels in patients with uterine adenomyosis
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Serum CA(125) levels in patients with ovarian endometriosis
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Serum CA(125) levels in patients with ovarian fibroma
Number of subjects: 492

Group type: COMPARATOR
Intervention: Serum CA(125) levels in benign pelvic mass
Number of subjects: 492

Group type: COMPARATOR
Intervention: Serum CA(125) levels in ovarian epithelial cancer (control group)
Number of subjects: 492
Study: 12296616

Group type: EXPERIMENTAL
Intervention: Antidepressants, especially selective serotonin uptake inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early identification and treatment
Number of subjects: 0
Study: 9833742

Group type: EXPERIMENTAL
Intervention: Triple therapy (zidovudine + 400 mg didanosine + 400 mg nevirapine)
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Dual therapy (zidovudine + 2.25 mg zalcitabine)
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Dual therapy (zidovudine alternating monthly with 400 mg didanosine)
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Dual therapy (zidovudine + 400 mg didanosine)
Number of subjects: 1313
Study: 7861603

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous administration of 20 micrograms.h‐1 of buprenorphine (Bu) with additional 20 micrograms of Bu using Baxter infusor BB+PCA
Number of subjects: 14

Group type: COMPARATOR
Intervention: Continuous epidural infusion of 0.4 mg of Bu and 46 ml of 0.25% bupivacaine daily (16.7 micrograms.h‐1 of Bu) using Baxter infusor 2 ml.h‐1 type
Number of subjects: 14
Study: 2692200

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pentoxifylline (PX)
Number of subjects: 70
Study: 4921234

Group type: EXPERIMENTAL
Intervention: 0.5% isoprenaline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.25% salbutamol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.5% salbutamol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1% salbutamol
Number of subjects: 24
Study: 11791962

Group type: EXPERIMENTAL
Intervention: Amodiaquine (30 and 35 mg/kg body weight)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 40
Study: 30622105

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pazopanib
Number of subjects: 0
Study: 30008194

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 150
Study: 27537841

Group type: EXPERIMENTAL
Intervention: elbasvir-grazoprevir for 12 weeks
Number of subjects: 301

Group type: COMPARATOR
Intervention: placebo for 12 weeks, then open-label elbasvir-grazoprevir for 12 weeks
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: elbasvir-grazoprevir for 12 weeks (assuming probable reinfections were responses)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 301
Study: 23942868

Group type: EXPERIMENTAL
Intervention: 200 mg CZP every 2 weeks (Q2W)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: 400 mg CZP every 4 weeks (Q4W)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 21949038

Group type: EXPERIMENTAL
Intervention: Plasma levels of chemokines and cytokines (TNF‐α, IL‐1β, IL‐6, IL‐8, MCP‐1, MIP‐1α, IFN‐γ) during painful crisis or at steady state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma levels of growth factors (VEGF, FGF, HGF) during painful crisis or at steady state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma levels of d‐Dimer during painful crisis or at steady state
Number of subjects: 0
Study: 21526671

Group type: EXPERIMENTAL
Intervention: Propofol administered for 30 seconds (Group A)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Propofol administered for 60 seconds (Group B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Propofol administered for 120 seconds (Group C)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 75
Study: 18034998

Group type: COMPARATOR
Intervention: 4 mg renzapride
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 mg renzapride
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.2 microM renzapride
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2 microM renzapride
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 microM renzapride
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 microM cisapride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisapride
Number of subjects: 0
Study: 14872557

Group type: EXPERIMENTAL
Intervention: Ritalin LA (bimodal release formulation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ritalin IR (immediate-release formulation)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ritalin LA (slow-, medium-, and fast-release formulations)
Number of subjects: 18
Study: 11996211

Group type: EXPERIMENTAL
Intervention: Sustained release metoclopramide (fasting state)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Immediate release metoclopramide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sustained release metoclopramide (high-fat meal)
Number of subjects: 16
Study: 9868632

Group type: EXPERIMENTAL
Intervention: Upper cervical manipulation
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sacroiliac manipulation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham/placebo
Number of subjects: 52
Study: 8593718

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg orally + ketoconazole shampoo 2% daily for 4 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg orally for 4 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Econazole nitrate 1% solution applied twice daily for 4 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Miconazole nitrate 2% cream applied twice daily for 4 weeks
Number of subjects: 62
Study: 2678932

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) with haloperidol (30 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Haloperidol (30 mg/day)
Number of subjects: 20
Study: 1090987

Group type: EXPERIMENTAL
Intervention: Five drug formulations
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30753262

Group type: EXPERIMENTAL
Intervention: Oral glutamine (5 g glutamine and 10 g maltodextrin) 3 times daily from 7 days before RT to 14 days after RT
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (15 g maltodextrin) 3 times daily from 7 days before RT to 14 days after RT
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both glutamine and placebo groups
Number of subjects: 71
Study: 28228106

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (15 or 20 mg twice daily)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 25907176

Group type: EXPERIMENTAL
Intervention: 100 mg canagliflozin once-daily (q.d.)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 300 mg canagliflozin once-daily (q.d.)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 100 mg canagliflozin twice-daily (b.i.d.)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 300 mg canagliflozin twice-daily (b.i.d.)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 100 mg canagliflozin
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 300 mg canagliflozin
Number of subjects: 34
Study: 24236791

Group type: EXPERIMENTAL
Intervention: Cisplatin and fluorouracil with panitumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin and fluorouracil without panitumumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 0
Study: 21186164

Group type: EXPERIMENTAL
Intervention: ACTS intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 19062107

Group type: EXPERIMENTAL
Intervention: Active counseling and more liberal oral fluid intake
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard fasting instructions according to hospital's procedure
Number of subjects: 116
Study: 16827026

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (FL Bond‐Shofu) applied in Group IA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Total-etch adhesive system (Prime Bond NT‐Dentsply/Caulk) applied in Group IB
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide exposure (33% for 30 minutes daily for five consecutive days) in Group I
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Group II) received no treatment
Number of subjects: 30
Study: 14688827

Group type: EXPERIMENTAL
Intervention: Hepatitis C virus positivity in patients with Hodgkin's disease
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Hepatitis G virus positivity in patients with Hodgkin's disease
Number of subjects: 111

Group type: COMPARATOR
Intervention: Comparison of hepatitis positive and negative patients
Number of subjects: 111
Study: 11763945

Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Maximum Strength dentifrice (5.0% potassium nitrate and 0.454% stannous fluoride in a silica base)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Fresh Mint Sensodyne dentifrice (5.0% potassium nitrate and 0.76% sodium monofluorophosphate in a dicalcium phosphate base)
Number of subjects: 97
Study: 8683153

Group type: EXPERIMENTAL
Intervention: CRP-mediated complement activation
Number of subjects: 9

Group type: COMPARATOR
Intervention: mAb OKT3 infusion
Number of subjects: 9